|
Dec 31
|
Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint
|
|
Dec 30
|
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
|
|
Nov 18
|
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
|
|
Nov 18
|
Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
|
|
Nov 15
|
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
|
|
Nov 15
|
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
|
|
Nov 15
|
Ouch: Why a Healthcare Selloff Really Hurts in Europe
|
|
Nov 14
|
Down -10.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)
|
|
Nov 14
|
Zacks.com featured highlights include Janus Henderson, Coastal Financial, Novartis, Apogee and InterDigital
|
|
Nov 13
|
Novartis (NVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
|
|
Nov 13
|
Down -9.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)
|
|
Nov 13
|
5 Low-Leverage Stocks to Buy Amid the Focus on Inflation Data
|
|
Nov 13
|
Q3 2024 Voyager Therapeutics Inc Earnings Call
|
|
Nov 13
|
Schrodinger announces expanded license agreement with Novartis
|
|
Nov 13
|
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing
|
|
Nov 13
|
Q3 2024 Legend Biotech Corp Earnings Call
|
|
Nov 13
|
Schrodinger Inc (SDGR) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...
|
|
Nov 13
|
Q3 2024 Schrodinger Inc Earnings Call
|
|
Nov 12
|
Top Stock Reports for Netflix, Salesforce & Cisco
|
|
Nov 12
|
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
|